Informationsbeauftragter: the German information officer role nobody tells you about (§ 74a AMG)

Ask a room of pharma professionals about the Stufenplanbeauftragter and several hands go up. Ask about the Informationsbeauftragter and you get silence. Yet § 74a of the German Medicines Act makes this appointment exactly as mandatory, for every company placing finished medicinal products on the German market. It may be the least described named function in German pharma, and that is precisely the opportunity if you work in medical affairs or regulatory and want the next step.

After 16 years recruiting in this industry, I can tell you: CVs that carry a statutory appointment get read differently. This guide explains what sits behind the title and how people actually get there.

What the Informationsbeauftragter owns

The statute puts it briefly: the Informationsbeauftragter is responsible for the scientific information about the company's medicinal products. Behind that sentence sits the whole chain of product communication. Does the Fachinformation match the authorisation? Does the package leaflet reflect the approved state? Is the trade-journal ad, the congress booth, the field-force material covered by the authorisation and permissible under advertising law?

In day-to-day terms, this person sits at the end of the materials approval process that many companies run as medical-legal-regulatory review. What they do not sign off does not ship. During a launch that makes it a pivot position, because between marketing pressure and the authorisation text, their signature decides. Add German drug advertising law, which is demanding in application and makes competitor warning letters a genuine business risk, and you understand why companies do not hand this role to beginners.

The legal basis in brief: § 74a AMG

The duty to appoint falls on pharmaceutical entrepreneurs placing finished medicinal products on the market, with exemptions for certain cases under § 13(2) AMG. The person needs the necessary expertise and the reliability required for the task. The authority is notified of the appointment and of every change in advance, immediately if a change is unforeseen. And § 74a(2) explicitly allows the Informationsbeauftragter to simultaneously be the Stufenplanbeauftragter.

As with its pharmacovigilance sibling, the law names no degree courses and no minimum years. The required expertise is an undefined legal term. If you can evidence closeness to the authorisation, the Fachinformation and promotional material, the door is open, whether your degree says medicine, pharmacy or a natural science.

Where the role sits in the org chart

A standalone full-time seat is the exception. The typical pattern is a double hat: the head of medical affairs, a senior medical advisor or the regulatory lead carries the appointment on top. In small companies it sometimes sits with a managing director who has the scientific background. That also explains why the role rarely appears in job ads on its own; it shows up as a clause inside medical and regulatory profiles, often in the second paragraph.

For your search, the practical consequence: an ad titled "Informationsbeauftragter" barely exists. Hunt for the medical or regulatory position the appointment is attached to, and bring the expertise for it. For the functions where these profiles live, see the guides to medical affairs careers and regulatory affairs careers in DACH pharma.

The qualifications that count in practice

Three things carry the appointment. First, the scientific base: a degree in medicine, pharmacy or a life science is the norm, because scientifically assessing claims is the core of the task. Second, materials closeness: experience with Fachinformationen and their maintenance, with approval workflows for promotional and training materials, with launch situations. Third, sure-footedness in German drug advertising law and the boundaries of the authorisation.

And the honest limitation for international readers: German is effectively non-negotiable here. The Fachinformation, the package materials and the advertising for the German market are written in German, and so is the correspondence with authorities and, in a warning-letter case, with lawyers. If you are building a German-market career and your German is on the way but not there yet, this is a role to grow toward, not to start with.

The entry routes that work in practice

The shortest route runs through medical information: if you answer healthcare professional enquiries, you already work daily at the seam between evidence and approved text. From there it goes via medical advisor stations into approval responsibility and finally the appointment. The second route comes from regulatory affairs via labelling and product information. A services market exists here too: law firms and consultancies supply Informationsbeauftragte to small companies that do not staff the function internally. Open roles at this interface are collected in the overview of medical information jobs in DACH.

Why the role is strategically underrated

The § 74a appointment is a seniority signal that cannot be faked. It documents that a company entrusted you with a statutory function, notified to the authority by name. In smaller companies that responsibility arrives years earlier than a director title would in a corporation. Once you have carried it, you negotiate your next position from different ground, and combining it with the Stufenplanbeauftragter makes a profile doubly valuable to the mid-market.

A note on salary

Quoting a salary band for the Informationsbeauftragter alone would be dishonest, because the appointment almost always rides on a carrier role whose level sets the pay. The mechanism is what you can rely on: the appointment raises the value of the carrier role, especially in the mid-market, and it belongs explicitly in every salary negotiation. How to build that argument is covered on the pharma salary negotiation page.

Frequently asked questions

Who needs to appoint an Informationsbeauftragter?

Every pharmaceutical entrepreneur placing finished medicinal products on the German market, from global groups to small mid-caps, with narrow exemptions under § 13(2) AMG. The role therefore exists at every company size, which is exactly what makes it interesting for career planning.

What qualifications does the law require?

§ 74a AMG requires the necessary expertise and the reliability needed for the task, without prescribing degrees or years. In practice the appointment is carried by people with a medical, pharmacy or life-science background and experience in medical information, medical affairs or regulatory affairs, because that is where the closeness to the Fachinformation and promotional materials lives.

What is the difference between the Informationsbeauftragter and the Stufenplanbeauftragter?

The Informationsbeauftragter owns scientific information: the match between labelling, package leaflet, Fachinformation, advertising and the authorisation. The Stufenplanbeauftragter owns pharmacovigilance: collecting and assessing drug risks. Both are mandatory appointments under the AMG, and § 74a(2) allows one person to carry both.

Is it a full-time job, and does it require German?

It is rarely a standalone full-time job; the appointment usually sits on top of a medical affairs or regulatory role, and under § 74a(2) AMG the same person may also be the Stufenplanbeauftragter. German is effectively indispensable: the Fachinformation, package materials and advertising for the German market are in German, as is authority and legal correspondence.

Sources

§ 74a AMG, Informationsbeauftragter (gesetze-im-internet.de, German)
§ 11a AMG, Fachinformation (gesetze-im-internet.de, German)
§ 13 AMG, manufacturing authorisation (gesetze-im-internet.de, German)
Heilmittelwerbegesetz, German drug advertising act (gesetze-im-internet.de)

© 27 July 2026 Andreas Schulz. All rights reserved. This article is career guidance, not legal advice; the statutory text prevails.